← Human Trials & Peer-Reviewed Studies
A pilot study of growth hormone administration in boys with predicted adult short stature and near-ending growth.
Plain-language guide to PMID 25641639 (2015): pilot controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 25641639
- Journal
- Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
- Year
- 2015
- Study type
- Controlled Clinical Trial
- Authors
- Rothenbuhler A et al. (4 authors)
- DOI
- 10.1016/j.ghir.2015.01.002
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.
1) To explore the effects of starting rhGH administration at time of near-ending growth in boys with ISS. 2) To search for predictors of response to rhGH.
Who Took Part
PubMed indexes the participants as teenagers and adults, men only.
Fifteen boys aged 15.5 ± 1 years terminating puberty were growing at a rate < 2 cm/6 months towards a predicted adult height (PAH) <-2.5 SDS.
Height increment (HI, adult height-starting height) and height gain (HG, adult height-PAH) were calculated.
How the Study Was Run
In design terms this was a pilot study.
It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.
When growth became less than 0.5 cm in 3 months or when height has reached 169 cm, rhGH was ceased.
Testosterone, growth velocity (GV), height, serum IGF-1, bone age (BA) at hand-wrist and knee score were measured at onset; IGF-1 and height were monitored every 3 months.
A formula for PAH was developed.
What Was Measured
Topics PubMed links to this paper include Adolescent Development, Age Determination by Skeleton, Body Height, Growth Charts, Growth Disorders, Human Growth Hormone and Pilot Projects.
Author keywords: Boys, End of puberty and Idiopathic short stature.
What This Means in Plain Language
The paper is a pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2015 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.